ArticleFrontiers in oncology2026
Case Report: Fatal pneumonitis caused by Camrelizumab and Erlotinib in a patient with metastatic pancreatic cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer continues to be one of the foremost contributors to cancer-related mortality. Erlotinib is a targeted agent that has shown a significant improvement in outcomes for advanced pancreatic cancer when administered alongside chemotherapy. Recent small-scale clinical studies have indicated promising results for the use of immune checkpoint inhibitors in the management of advanced pancreatic cancer. We present a case involving a 70-year-old male patient who presented with abdominal pain and a subcutaneous nodular lesion located in the frontal region. The patient was ultimately diagnosed with metastatic pancreatic cancer and was refractory to gemcitabine and nab-paclitaxel. Following treatment with Camrelizumab, Erlotinib and chemotherapy in the second-line setting, the patient developed fatal pneumonitis. Despite receiving optimal treatment with steroid and antibiotic therapy, the patient ultimately succumbed to respiratory failure. This case demonstrates that the combination of immunotherapy and Erlotinib may not constitute a safe therapeutic strategy for patients with advanced pancreatic cancer, as it can lead to severe pneumonitis. Significant caution should also be exercised when administering Erlotinib to patients who have recently undergone immune checkpoint inhibitor therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.